Disease Overview
Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.
Market Snapshot
Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.
Market Snapshot
- Increased use of Entresto and a full pipeline will revitalize the mature CHF market.
- Novel CHF treatments have yet to alter prescribing practices from traditional ACE inhibitors and beta blockers.
- CHF prevalence rises with age, with 55–84 years comprising three-quarters of all diagnosed prevalent cases in adults.
- Entresto has overcome initial barriers to uptake and has the potential to change CHF treatment practices.
- Despite a full pipeline it is unlikely that any candidates have the potential to significantly change treatment practices.
- Entresto’s budget impact is moderate due to lower than expected physician uptake.
Table of Contents
FORECAST: CHRONIC HEART FAILURE (Published on 21 March 2019)
- Overview
- Recent Forecast Updates
- Market Dynamics
- Forecast And Future Trends
- Market Definition And Methodology
- Primary Research Methodology
- Bibliography
- Product Profile: Corlanor
- Product Profile: Entresto
- Product Profile (Late Stage): Farxiga
- Product Profile (Late Stage): Jardiance
- Product Profile (Late Stage): Omecamtiv Mecarbil
- Product Profile (Late Stage): Vericiguat
TREATMENT: CHRONIC HEART FAILURE (Published on 21 March 2019)
- Overview
- Primary Research Methodology
- Disease Definition And Diagnosis
- Patient Segmentation
- Current Treatment Options
- Prescribing Trends: Chf With Reduced Ejection Fraction
- Prescribing Trends: Chf With Preserved Ejection Fraction
- Compliance Rates
EPIDEMIOLOGY: CHRONIC HEART FAILURE (Published on 03 January 2019)
- Overview
- Disease Background
- Methodology
- Forecast
- Bibliography
- Appendix: Additional Sources
MARKETED DRUGS: CHRONIC HEART FAILURE (Published on 21 March 2019)
- Overview
- Product Overview
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Receptor Blockers
- Beta Blockers
- Aldosterone Antagonists
- Other Drug Classes
- Product Profile: Corlanor
- Product Profile: Entresto
CHRONIC HEART FAILURE PRICING, REIMBURSEMENT, AND ACCESS (Published on 13 April 2018)
- Overview
- Executive Summary
- Regulatory Labels And Guidelines
- Global Access Levers
- Evidence And Value
- Access To Recently Approved And Pipeline Products
- Pricing
- Us
- Canada
- France
- Germany
- Italy
- Spain
- Uk
- Methodology
PIPELINE: CHRONIC HEART FAILURE (Published on 21 March 2019)
- Overview
- Clinical Pipeline Overview
- Additional Pharma Intelligence Pipeline Resources
- Product Profile (Late Stage): Arry-797
- Product Profile (Late Stage): Farxiga
- Product Profile (Late Stage): Jardiance
- Product Profile (Late Stage): Mpc-150-Im
- Product Profile (Late Stage): Mavacamten
- Product Profile (Late Stage): Omecamtiv Mecarbil
- Product Profile (Late Stage): Vericiguat
LIST OF FIGURES
Figure 1: The author's assessment summary of key marketed and pipeline drugs for chronic heart failure
Figure 2: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 3: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017–26
Figure 5: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017–26
Figure 6: Chronic heart failure drug sales in the US, by class, 2017–26
Figure 7: Chronic heart failure drug sales in the five major EU markets, by country, 2017–26
Figure 8: Chronic heart failure drug sales in the five major EU markets, by class, 2017–26
Figure 9: Chronic heart failure drug sales in Japan, by class, 2017–26
Figure 10: Methodology flow for The author's chronic heart failure forecast
Figure 11: Price sources and calculations, by country
Figure 12: The author's drug assessment summary of Corlanor for CHF
Figure 13: The author's drug assessment summary of Corlanor for CHF
Figure 14: Corlanor sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 15: The author's drug assessment summary of Entresto for CHF
Figure 16: The author's drug assessment summary of Entresto for CHF
Figure 17: Entresto sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: The author's drug assessment summary of Farxiga for CHF
Figure 19: The author's drug assessment summary of Farxiga for CHF
Figure 20: Farxiga sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 21: The author's drug assessment summary of Jardiance for CHF
Figure 22: The author's drug assessment summary of Jardiance for CHF
Figure 23: Jardiance sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 25: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 26: Omecamtiv mecarbil sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 27: The author's drug assessment summary of vericiguat for CHF
Figure 28: The author's drug assessment summary of vericiguat for CHF
Figure 29: Vericiguat sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Diagnostic flow chart for patients with suspected heart failure
Figure 31: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
Figure 32: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
Figure 33: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
Figure 34: Percentage of patients with HFrEF in each NYHA class, by country
Figure 35: Percentage of patients with HFpEF in each NYHA class, by country
Figure 36: Percentage of HFrEF patients receiving each treatment type, by NYHA class
Figure 37: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
Figure 38: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
Figure 39: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
Figure 40: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
Figure 41: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
Figure 42: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
Figure 43: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
Figure 44: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
Figure 45: Top three drug regimens for first-line treatment of class I HFrEF, by country
Figure 46: Top three drug regimens for second-line treatment of class I HFrEF, by country
Figure 47: Top three drug regimens for first-line treatment of class II–III HFrEF, by country
Figure 48: Top three drug regimens for second-line treatment of class II–III HFrEF, by country
Figure 49: Top three drug regimens for first-line treatment of class IV HFrEF, by country
Figure 50: Top three drug regimens for second-line treatment of class IV HFrEF, by country
Figure 51: Percentage of HFpEF patients receiving each treatment type, by NYHA class
Figure 52: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
Figure 53: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
Figure 54: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
Figure 55: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
Figure 56: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
Figure 57: Top three drug regimens for first-line treatment of class I HFpEF, by country
Figure 58: Top three drug regimens for second-line treatment of class I HFpEF, by country
Figure 59: Top three drug regimens for first-line treatment of class II–III HFpEF, by country
Figure 60: Top three drug regimens for second-line treatment of class II–III HFpEF, by country
Figure 61: Top three drug regimens for first-line treatment of class IV HFpEF, by country
Figure 62: Top three drug regimens for second-line treatment of class IV HFpEF, by country
Figure 63: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
Figure 64: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Figure 65: The author's drug assessment summary of Corlanor for CHF
Figure 66: The author's drug assessment summary of Corlanor for CHF
Figure 67: Corlanor sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 68: The author's drug assessment summary of Entresto for CHF
Figure 69: The author's drug assessment summary of Entresto for CHF
Figure 70: Entresto sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 71: European Society of Cardiology Heart Failure guidelines
Figure 72: American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines
Figure 73: Price sources and calculations for the US and EU, by country
Figure 74: The author's drug assessment summary of ARRY-797 for CHF
Figure 75: The author's drug assessment summary of ARRY-797 for CHF
Figure 76: The author's drug assessment summary of Farxiga for CHF
Figure 77: The author's drug assessment summary of Farxiga for CHF
Figure 78: Farxiga sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 79: The author's drug assessment summary of Jardiance for CHF
Figure 80: The author's drug assessment summary of Jardiance for CHF
Figure 81: Jardiance sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 82: The author's drug assessment summary of MPC-150-IM for CHF
Figure 83: The author's drug assessment summary of MPC-150-IM for CHF
Figure 84: The author's drug assessment summary of mavacamten for CHF
Figure 85: The author's drug assessment summary of mavacamten for CHF
Figure 86: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 87: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 88: Omecamtiv mecarbil sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 89: The author's drug assessment summary of vericiguat for CHF
Figure 90: The author's drug assessment summary of vericiguat for CHF
Figure 91: Vericiguat sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 2: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017–26
Figure 3: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
Figure 4: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017–26
Figure 5: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017–26
Figure 6: Chronic heart failure drug sales in the US, by class, 2017–26
Figure 7: Chronic heart failure drug sales in the five major EU markets, by country, 2017–26
Figure 8: Chronic heart failure drug sales in the five major EU markets, by class, 2017–26
Figure 9: Chronic heart failure drug sales in Japan, by class, 2017–26
Figure 10: Methodology flow for The author's chronic heart failure forecast
Figure 11: Price sources and calculations, by country
Figure 12: The author's drug assessment summary of Corlanor for CHF
Figure 13: The author's drug assessment summary of Corlanor for CHF
Figure 14: Corlanor sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 15: The author's drug assessment summary of Entresto for CHF
Figure 16: The author's drug assessment summary of Entresto for CHF
Figure 17: Entresto sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 18: The author's drug assessment summary of Farxiga for CHF
Figure 19: The author's drug assessment summary of Farxiga for CHF
Figure 20: Farxiga sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 21: The author's drug assessment summary of Jardiance for CHF
Figure 22: The author's drug assessment summary of Jardiance for CHF
Figure 23: Jardiance sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 24: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 25: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 26: Omecamtiv mecarbil sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 27: The author's drug assessment summary of vericiguat for CHF
Figure 28: The author's drug assessment summary of vericiguat for CHF
Figure 29: Vericiguat sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 30: Diagnostic flow chart for patients with suspected heart failure
Figure 31: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
Figure 32: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
Figure 33: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
Figure 34: Percentage of patients with HFrEF in each NYHA class, by country
Figure 35: Percentage of patients with HFpEF in each NYHA class, by country
Figure 36: Percentage of HFrEF patients receiving each treatment type, by NYHA class
Figure 37: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
Figure 38: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
Figure 39: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
Figure 40: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
Figure 41: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
Figure 42: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
Figure 43: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
Figure 44: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
Figure 45: Top three drug regimens for first-line treatment of class I HFrEF, by country
Figure 46: Top three drug regimens for second-line treatment of class I HFrEF, by country
Figure 47: Top three drug regimens for first-line treatment of class II–III HFrEF, by country
Figure 48: Top three drug regimens for second-line treatment of class II–III HFrEF, by country
Figure 49: Top three drug regimens for first-line treatment of class IV HFrEF, by country
Figure 50: Top three drug regimens for second-line treatment of class IV HFrEF, by country
Figure 51: Percentage of HFpEF patients receiving each treatment type, by NYHA class
Figure 52: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
Figure 53: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
Figure 54: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
Figure 55: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
Figure 56: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
Figure 57: Top three drug regimens for first-line treatment of class I HFpEF, by country
Figure 58: Top three drug regimens for second-line treatment of class I HFpEF, by country
Figure 59: Top three drug regimens for first-line treatment of class II–III HFpEF, by country
Figure 60: Top three drug regimens for second-line treatment of class II–III HFpEF, by country
Figure 61: Top three drug regimens for first-line treatment of class IV HFpEF, by country
Figure 62: Top three drug regimens for second-line treatment of class IV HFpEF, by country
Figure 63: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
Figure 64: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Figure 65: The author's drug assessment summary of Corlanor for CHF
Figure 66: The author's drug assessment summary of Corlanor for CHF
Figure 67: Corlanor sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 68: The author's drug assessment summary of Entresto for CHF
Figure 69: The author's drug assessment summary of Entresto for CHF
Figure 70: Entresto sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 71: European Society of Cardiology Heart Failure guidelines
Figure 72: American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines
Figure 73: Price sources and calculations for the US and EU, by country
Figure 74: The author's drug assessment summary of ARRY-797 for CHF
Figure 75: The author's drug assessment summary of ARRY-797 for CHF
Figure 76: The author's drug assessment summary of Farxiga for CHF
Figure 77: The author's drug assessment summary of Farxiga for CHF
Figure 78: Farxiga sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 79: The author's drug assessment summary of Jardiance for CHF
Figure 80: The author's drug assessment summary of Jardiance for CHF
Figure 81: Jardiance sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 82: The author's drug assessment summary of MPC-150-IM for CHF
Figure 83: The author's drug assessment summary of MPC-150-IM for CHF
Figure 84: The author's drug assessment summary of mavacamten for CHF
Figure 85: The author's drug assessment summary of mavacamten for CHF
Figure 86: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 87: The author's drug assessment summary of omecamtiv mecarbil for CHF
Figure 88: Omecamtiv mecarbil sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
Figure 89: The author's drug assessment summary of vericiguat for CHF
Figure 90: The author's drug assessment summary of vericiguat for CHF
Figure 91: Vericiguat sales for CHF across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
Table 1: Chronic heart failure – current and future market dynamics analysis
Table 2: Exchange rates used for calculating prices
Table 3: Cardiologists surveyed for the chronic heart failure primary research study, 2018
Table 4: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 5: Corlanor drug profile
Table 6: Approval history of Corlanor for CHF in the US and major EU markets
Table 7: Corlanor pivotal trials for CHF
Table 8: Corlanor for CHF – SWOT analysis
Table 9: Entresto drug profile
Table 10: Approval history of Entresto for CHF in the US and major EU markets
Table 11: Entresto pivotal trials for CHF
Table 12: Entresto for CHF – SWOT analysis
Table 13: Farxiga drug profile
Table 14: Farxiga pivotal trials for CHF
Table 15: Farxiga for CHF – SWOT analysis
Table 16: Jardiance drug profile
Table 17: Jardiance pivotal trials for CHF
Table 18: Jardiance for CHF – SWOT analysis
Table 19: Omecamtiv mecarbil drug profile
Table 20: Omecamtiv mecarbil pivotal trials for CHF
Table 21: Omecamtiv mecarbil for CHF – SWOT analysis
Table 22: Vericiguat drug profile
Table 23: Vericiguat pivotal trial for CHF
Table 24: Vericiguat early trials for CHF
Table 25: Vericiguat for CHF – SWOT analysis
Table 26: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 27: Common laboratory test abnormalities in chronic heart failure
Table 28: Definitions of HFrEF and HFpEF
Table 29: New York Heart Association functional classification based on severity of symptoms and physical activity
Table 30: Comparison of ACCF/AHA stages of HF with NYHA functional classification
Table 31: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
Table 32: NYHA functional classes I–IV, classification summary
Table 33: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
Table 34: Sources used for the previous epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country (published 9 October 2017)
Table 35: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Table 36: Profiled key marketed drugs for chronic heart failure
Table 37: Angiotensin-converting enzyme inhibitors in CHF, class overview
Table 38: Angiotensin receptor blockers in CHF, class overview
Table 39: Beta blockers in CHF, class overview
Table 40: Aldosterone antagonists in CHF, class overview
Table 41: Other drug class overview
Table 42: Corlanor drug profile
Table 43: Approval history of Corlanor for CHF in the US and major EU markets
Table 44: Corlanor pivotal trials for CHF
Table 45: Corlanor for CHF – SWOT analysis
Table 46: Entresto drug profile
Table 47: Approval history of Entresto for CHF in the US and major EU markets
Table 48: Entresto pivotal trials for CHF
Table 49: Entresto for CHF – SWOT analysis
Table 50: Regulatory labels for Entresto in the US, Japan, and five major EU markets
Table 51: Reimbursement restrictions for Entresto across the US and five surveyed EU markets
Table 52: Primary and secondary care prescribing of Entresto in the five major EU markets
Table 53: Use of efficiency audits for Entresto in the five major EU markets
Table 54: Payer concerns surrounding the Phase III PARADIGM-HF patient population
Table 55: Payer views on the primary and secondary endpoints used in the Phase III PARADIGM-HF trial
Table 56: Impact of reduction in CHF hospitalization for Entresto across the US and five major EU markets
Table 57: Impact of Entresto’s HRQoL benefits across the five major EU markets
Table 58: Benefits of Jardiance versus Entresto
Table 59: Pricing of Entresto in the US and five major EU markets, by country
Table 60: Formulary placement of Entresto in selected commercial formularies
Table 61: Formulary placement of Entresto in selected Medicare Part D formularies
Table 62: Prior authorization criteria for Entresto in eight major health plans
Table 63: CADTH assessment of Entresto
Table 64: Transparency Committee's ASMR ratings and pricing implications
Table 65: Transparency Committee's SMR ratings and pricing implications
Table 66: Transparency Committee's assessment of Entresto
Table 67: G-BA assessment of Entresto
Table 68: Reimbursement conditions for Entresto in Italy
Table 69: National and regional reimbursement decisions in Spain
Table 70: NICE assessment of Entresto
Table 71: SMC assessment of Entresto
Table 72: Exchange rates used for calculating branded drug prices
Table 73: Profiled pipeline products in development for chronic heart failure
Table 74: ARRY-797 drug profile
Table 75: ARRY-797 clinical trials for CHF
Table 76: ARRY-797 for CHF – SWOT analysis
Table 77: Farxiga drug profile
Table 78: Farxiga pivotal trials for CHF
Table 79: Farxiga for CHF – SWOT analysis
Table 80: Jardiance drug profile
Table 81: Jardiance pivotal trials for CHF
Table 82: Jardiance for CHF – SWOT analysis
Table 83: MPC-150-IM drug profile
Table 84: MPC-150-IM clinical trials for CHF
Table 85: MPC-150-IM for CHF – SWOT analysis
Table 86: Mavacamten drug profile
Table 87: Mavacamten pivotal trial for CHF
Table 88: Mavacamten Phase II trials for CHF
Table 89: Mavacamten for CHF – SWOT analysis
Table 90: Omecamtiv mecarbil drug profile
Table 91: Omecamtiv mecarbil pivotal trials for CHF
Table 92: Omecamtiv mecarbil for CHF – SWOT analysis
Table 93: Vericiguat drug profile
Table 94: Vericiguat pivotal trial for CHF
Table 95: Vericiguat early trials for CHF
Table 96: Vericiguat for CHF – SWOT analysis
Table 2: Exchange rates used for calculating prices
Table 3: Cardiologists surveyed for the chronic heart failure primary research study, 2018
Table 4: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 5: Corlanor drug profile
Table 6: Approval history of Corlanor for CHF in the US and major EU markets
Table 7: Corlanor pivotal trials for CHF
Table 8: Corlanor for CHF – SWOT analysis
Table 9: Entresto drug profile
Table 10: Approval history of Entresto for CHF in the US and major EU markets
Table 11: Entresto pivotal trials for CHF
Table 12: Entresto for CHF – SWOT analysis
Table 13: Farxiga drug profile
Table 14: Farxiga pivotal trials for CHF
Table 15: Farxiga for CHF – SWOT analysis
Table 16: Jardiance drug profile
Table 17: Jardiance pivotal trials for CHF
Table 18: Jardiance for CHF – SWOT analysis
Table 19: Omecamtiv mecarbil drug profile
Table 20: Omecamtiv mecarbil pivotal trials for CHF
Table 21: Omecamtiv mecarbil for CHF – SWOT analysis
Table 22: Vericiguat drug profile
Table 23: Vericiguat pivotal trial for CHF
Table 24: Vericiguat early trials for CHF
Table 25: Vericiguat for CHF – SWOT analysis
Table 26: Cardiologists surveyed for the chronic heart failure primary research study, 2017
Table 27: Common laboratory test abnormalities in chronic heart failure
Table 28: Definitions of HFrEF and HFpEF
Table 29: New York Heart Association functional classification based on severity of symptoms and physical activity
Table 30: Comparison of ACCF/AHA stages of HF with NYHA functional classification
Table 31: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
Table 32: NYHA functional classes I–IV, classification summary
Table 33: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
Table 34: Sources used for the previous epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country (published 9 October 2017)
Table 35: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
Table 36: Profiled key marketed drugs for chronic heart failure
Table 37: Angiotensin-converting enzyme inhibitors in CHF, class overview
Table 38: Angiotensin receptor blockers in CHF, class overview
Table 39: Beta blockers in CHF, class overview
Table 40: Aldosterone antagonists in CHF, class overview
Table 41: Other drug class overview
Table 42: Corlanor drug profile
Table 43: Approval history of Corlanor for CHF in the US and major EU markets
Table 44: Corlanor pivotal trials for CHF
Table 45: Corlanor for CHF – SWOT analysis
Table 46: Entresto drug profile
Table 47: Approval history of Entresto for CHF in the US and major EU markets
Table 48: Entresto pivotal trials for CHF
Table 49: Entresto for CHF – SWOT analysis
Table 50: Regulatory labels for Entresto in the US, Japan, and five major EU markets
Table 51: Reimbursement restrictions for Entresto across the US and five surveyed EU markets
Table 52: Primary and secondary care prescribing of Entresto in the five major EU markets
Table 53: Use of efficiency audits for Entresto in the five major EU markets
Table 54: Payer concerns surrounding the Phase III PARADIGM-HF patient population
Table 55: Payer views on the primary and secondary endpoints used in the Phase III PARADIGM-HF trial
Table 56: Impact of reduction in CHF hospitalization for Entresto across the US and five major EU markets
Table 57: Impact of Entresto’s HRQoL benefits across the five major EU markets
Table 58: Benefits of Jardiance versus Entresto
Table 59: Pricing of Entresto in the US and five major EU markets, by country
Table 60: Formulary placement of Entresto in selected commercial formularies
Table 61: Formulary placement of Entresto in selected Medicare Part D formularies
Table 62: Prior authorization criteria for Entresto in eight major health plans
Table 63: CADTH assessment of Entresto
Table 64: Transparency Committee's ASMR ratings and pricing implications
Table 65: Transparency Committee's SMR ratings and pricing implications
Table 66: Transparency Committee's assessment of Entresto
Table 67: G-BA assessment of Entresto
Table 68: Reimbursement conditions for Entresto in Italy
Table 69: National and regional reimbursement decisions in Spain
Table 70: NICE assessment of Entresto
Table 71: SMC assessment of Entresto
Table 72: Exchange rates used for calculating branded drug prices
Table 73: Profiled pipeline products in development for chronic heart failure
Table 74: ARRY-797 drug profile
Table 75: ARRY-797 clinical trials for CHF
Table 76: ARRY-797 for CHF – SWOT analysis
Table 77: Farxiga drug profile
Table 78: Farxiga pivotal trials for CHF
Table 79: Farxiga for CHF – SWOT analysis
Table 80: Jardiance drug profile
Table 81: Jardiance pivotal trials for CHF
Table 82: Jardiance for CHF – SWOT analysis
Table 83: MPC-150-IM drug profile
Table 84: MPC-150-IM clinical trials for CHF
Table 85: MPC-150-IM for CHF – SWOT analysis
Table 86: Mavacamten drug profile
Table 87: Mavacamten pivotal trial for CHF
Table 88: Mavacamten Phase II trials for CHF
Table 89: Mavacamten for CHF – SWOT analysis
Table 90: Omecamtiv mecarbil drug profile
Table 91: Omecamtiv mecarbil pivotal trials for CHF
Table 92: Omecamtiv mecarbil for CHF – SWOT analysis
Table 93: Vericiguat drug profile
Table 94: Vericiguat pivotal trial for CHF
Table 95: Vericiguat early trials for CHF
Table 96: Vericiguat for CHF – SWOT analysis
